Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
HERE TO PURCHASE ►
NOTE: Pharmacists or Pharmacy Technicians that attended this live CE webinar that was held on March 28, 2017, AND received CE credit are NOT eligible to also receive CE credit for this home-study activity.
A variety of insulin pen injectors (collectively called "pens") are currently
available in the US, with more products and concentrations becoming readily available
every year. Intended primarily to facilitate easy and accurate outpatient self-administration
of insulin, pen devices are also used in many hospitals across the US. There are a
number of benefits to choosing insulin pens over vials including having a pre-labeled
product in a ready-to-use form, lessening insulin waste, and giving the patient an
opportunity to master administration techniques with the same device they are likely
to use to administer insulin after discharge.
Despite these advantages, a number of hospitals have been significantly concerned about the use of pen devices because of the potential for blood-borne pathogen transmission if the pen device would be accidentally used on more than one patient. Such inadvertent multi-patient use of pen devices has been widely publicized in the media, effecting thousands of patients as far back as 2009.
While many organizations using pens have adopted a number of manual strategies to reduce the frequency of pen mix up or reuse, none are quite so promising for safety than the best practice distribution of a patient-specific pen from pharmacy with support of an integrated CPOE and barcoding system. Join ISMP and our expert faculty as they describe the challenges faced at their organizations to ensure the safety of insulin pen use, and the steps they each have taken to implement best practices to enhance the safety of insulin pen use. In addition, our speakers will describe a number of risk identification measures used to alert practitioners to the potential use of an insulin pen on more than one patient.
The target audience for this activity includes Hospital and Health System Leadership,
Quality and Risk Management Leaders, Physician, Pharmacy, and Nursing Leaders, Patient
and Medication Safety Officers, Frontline Practitioners, Certified Diabetic Educators,
and Clinical Pharmacy Staff.
At the completion of this webinar, the participant will be able to:
Michael Cohen, RPh, MS, ScD (hon.), DPS (hon.), FASHP
Amy F. Rosenberg PharmD, BCPS
Medication Safety Specialist
Shands at the University of Florida
Department of Pharmacy Services
Melissa Carlson Pharm.D., BCPS
Assistant Director of Clinical Services and Medication Safety Officer
University of Minnesota Medical Center
Release Date: March 28, 2017
Expiration Date: January 31, 2019
This webinar is approved for 1.5 hours of Pharmacy Continuing Education and 1.0 hours of Nursing Continuing Education. There is no additional charge for the continuing education credits for this webinar.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.5 hours (0.15 CEUs) for both pharmacists and pharmacy technicians. Educational Review Systems is also approved for pharmacy continuing education by the state of Florida.
HERE TO PURCHASE ►
(On-Demand Webinar Recording, $125*)
*Up to 15 participants can access the On-Demand Recording and claim CE.
|Institute for Safe Medication Practices (ISMP)
200 Lakeside Drive, Suite 200, Horsham, PA 19044
Phone: (215) 947-7797 www.ismp.org
For registration questions, contact ProCE at 1-800-748-7795.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.